Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 624 of 5804
-
Could a vaccine fight Alzheimer's? new trial begins
⭐️ VACCINE ⭐️ OngoingPhase 1 clinical trial of AV-1959 amyloid-β vaccine for Alzheimer's disease (AD).
Phase: PHASE1 • Sponsor: Institute for Molecular Medicine • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:00 UTC
-
Blood test could detect hidden pancreatic tumors
Diagnosis Recruiting nowThis prospective study aims to evaluate the sensitivity and specificity of an integrated model using fragmentomic profiles of plasma cell-free DNA for early detection of pancreatic neuroendocrine tumors and differential diagnosis of solid pancreatic tumors.
Sponsor: Fudan University • Aim: Diagnosis
Last updated Jun 27, 2026 12:00 UTC
-
New program aims to protect pregnant women from domestic violence in china
Prevention Recruiting nowThe proposed project addresses intimate partner violence (IPV) against pregnant women, which is a serious social and health issue. Pregnant women represent a particularly vulnerable population of IPV survivors in China, who have been largely underserved. There have been no interv…
Phase: NA • Sponsor: University of Texas at Austin • Aim: Prevention
Last updated Jun 27, 2026 13:05 UTC
-
New hope for chinese adults with Hard-to-Treat leukemia
Disease control CompletedThis is an open-label, single-arm, multicenter study in Chinese patients with relapsed or refractory CD22-positive B-cell ALL. The objective of the study is to confirm the efficacy, safety, and PK of inotuzumab ozogamicin in patients with relapsed or refractory B-cell ALL from ma…
Phase: PHASE4 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Can a No-Fridge migraine shot replace botox?
Disease control Recruiting nowChronic migraine (CM) is a disabling disorder that sidelines active duty personnel and diminishes their quality of life. It affects 1.3% to 2.4% of the general population. These numbers increase in active duty personnel, especially those returning from deployment, as well as in v…
Phase: PHASE3 • Sponsor: Naval Medical Center Camp Lejeune • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Triple threat: new combo tackles rare lung cancer
Disease control Recruiting nowIn this multicenter phase I/II trial, the programmed death-ligand 1 (PD-L1) inhibitor atezolizumab and dendritic cells (DCs) loaded with the mesothelioma-associated tumor antigen WT1 will be integrated into platinum/pemetrexed-based first-line chemotherapy for the treatment of ep…
Phase: PHASE1, PHASE2 • Sponsor: University Hospital, Antwerp • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Immune cells engineered to hunt two targets in brain cancer
Disease control OngoingThis is an open-label phase 1 study to assess the safety and feasibility of autologous T cells co-expressing two CARs targeting the cryptic EGFR epitope 806 and IL13Ra2 (referred to as "CART-EGFR-IL13Ra2 cells") in patients with EGFR-amplified glioblastoma, IDH-wildtype that has …
Phase: PHASE1 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Heart drug could boost radiation for brain tumors in lung cancer patients
Disease control Recruiting nowThe goal of this interventional phase III clinical trial is to evaluate objective intracranial response rate (iORR) after a treatment with total cranial radiation therapy plus concomitant transdermal nitroglycerin (NTG) addition or total cranial radiation therapy only in patients…
Phase: NA • Sponsor: Instituto Nacional de Cancerologia de Mexico • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New Triple-Drug attack shows promise for Hard-to-Treat breast cancer
Disease control Recruiting nowThis research is being done to evaluate the safety and effectiveness of a drug currently known as VS-6766 in combination with the drugs abemaciclib and fulvestrant in HR+/HER2-negative breast cancer. The names of the study drugs involved in this study are: * VS-6766 * Abemacicl…
Phase: PHASE1, PHASE2 • Sponsor: Adrienne G. Waks • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New combo therapy targets melanoma in the brain
Disease control Recruiting nowTo learn if giving nivolumab in combination with relatlimab can help to control melanoma that has spread to the brain (melanoma with brain metastases). The safety and side effects of the study drug combination will also be studied.
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New pill cocktail aims to control Hard-to-Treat breast cancer
Disease control OngoingThe purpose of this clinical trial is to learn about the safety and effects of the study medicine (called ARV-471) when given together with other medicines for the potential treatment of advanced or metastatic breast cancer. This study is seeking participants who have breast can…
Phase: PHASE1, PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Can your genes guide better mental health meds? new trial aims to find out
Disease control Recruiting nowA 24-week, patient- and rater-blinded, two-arm, parallel-group controlled, and multi-centre randomized clinical trial (RCT) to establish the benefits of pharmacogenetics-informed pharmacotherapy versus dosing as usual (DAU) in psychiatric patients suffering from mood, anxiety, or…
Phase: NA • Sponsor: Parnassia Groep • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Engineered immune cells take on tough lymphoma
Disease control OngoingThe purpose of this research is to evaluate if study therapy, 19(T2)28z1xx TRAC-chimeric antigen receptor (CAR) T cells, may be an effective treatment for people with relapsed/refractory B-cell lymphoma. Researchers will also evaluate if this study therapy is safe, and to look fo…
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Simple changes to electrode placement could boost heart shock success
Disease control Recruiting nowAtrial fibrillation is the most common heart rhythm disorder (arrhythmia) worldwide. Nearly 40 million people are affected by atrial fibrillation worldwide, and this number is expected to increase by over 50% by 2050. Atrial fibrillation can cause strokes, heart attacks, heart fa…
Phase: NA • Sponsor: McMaster University • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New cocktail aims to shrink rectal tumors before surgery
Disease control Recruiting nowColorectal cancer of Mismatch Repair-proficient (pMMR)/ Microsatellite Stability (MSS) accounts for approximately 85% of all colorectal cancer patients, which might be insensitive to immunotherapy. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body…
Phase: PHASE2 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New tool could prevent deadly complication during heart valve procedure
Disease control CompletedBackground: Replacing a valve in the heart can save many people's lives. The procedure is called transcatheter aortic valve replacement (TAVR). In rare cases, a flap of tissue called a leaflet can shift during TAVR; the leaflet may block blood flow to the coronary arteries, whic…
Phase: NA • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New cocktail targets Hard-to-Treat stomach cancer
Disease control OngoingThis was an open-label, phase 1/2 study to evaluate safety, tolerability, pharmacokinetics, and antitumor activity of ASKB589 in combination with CAPOX and PD-1 inhibitors in first-line treatment of patients with locally advanced, recurrent, or metastatic gastric and esophagogast…
Phase: PHASE1, PHASE2 • Sponsor: AskGene Pharma, Inc. • Aim: Disease control
Last updated Jun 26, 2026 16:04 UTC
-
New eczema drug shows promise in major trial
Disease control CompletedThe coprimary objectives of the study are to: * evaluate the efficacy of rocatinlimab in combination with topical corticosteroid and/or topical calcineurin inhibitor (TCS/TCI), compared with placebo in combination with TCS/TCI at Week 24, assessed using Validated Investigator's …
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New pill shows promise for tough blood cancer
Disease control OngoingThis is an open-label, single arm, multi-center Phase 2 study of oral Rocbrutinib in patients with mantle cell lymphoma who are failed or relapsed after remission or intolerated to Bruton's tyrosine kinase (BTK) inhibitor.
Phase: PHASE2 • Sponsor: Guangzhou Lupeng Pharmaceutical Company LTD. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New hope for hard-to-treat BRAF cancers: drug targets tumor drivers
Disease control Recruiting nowThe objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with locally advanced or metastatic solid tumors, or recurrent or progressive primary central nervous system (CNS) tumors harboring BRAF fusions, or in participants with r…
Phase: PHASE2 • Sponsor: Fore Biotherapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC